MY
Myriad Genetics
MYGN·NASDAQSalt Lake City UTFounded 19912,500 employees
Mid CapbiotechPublicOncology
Platform: Genetic Testing
Market Cap
$3B
All Drugs
3
Clinical Trials
7
Failed / Terminated
2
FDA Approved
0
Stock Price & Catalysts (MYGN)
Loading MYGN stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Lisosotorasib | MYG-9809 | Phase 3 | 3 | GPRC5D | MCCCSU | ||
| MYG-309 | MYG-309 | NDA/BLA | 2 | EGFR | NBMM | ||
| MYG-2072 | MYG-2072 | Phase 2 | 2 | Aβ | MesoBCC |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (7)